Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid …
W Katchamart, J Trudeau, V Phumethum… - Annals of the …, 2009 - ard.bmj.com
Objective: To evaluate the efficacy and toxicity of methotrexate (MTX) monotherapy
compared with MTX combination with non-biological disease-modifying antirheumatic drugs (…
compared with MTX combination with non-biological disease-modifying antirheumatic drugs (…
Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis
W Katchamart, J Trudeau… - Cochrane database …, 1996 - cochranelibrary.com
Background Methotrexate (MTX) is among the most effective disease modifying anti‐rheumatic
drugs (DMARDs) in rheumatoid arthritis (RA) with less toxicity and better tolerability. …
drugs (DMARDs) in rheumatoid arthritis (RA) with less toxicity and better tolerability. …
CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides
…, R Taylor-Gjevre, TE Towheed, J Trudeau… - The Journal of …, 2016 - jrheum.org
Objective. The Canadian Vasculitis research network (CanVasc) is composed of physicians
from different medical specialties and researchers with expertise in vasculitis. One of its aims …
from different medical specialties and researchers with expertise in vasculitis. One of its aims …
CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update
…, DG Rumsey, TE Towheed, J Trudeau… - The Journal of …, 2021 - jrheum.org
Objective In 2015, the Canadian Vasculitis Research Network (CanVasc) created
recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated …
recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated …
CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum
…, M Soowamber, TE Towheed, J Trudeau… - …, 2023 - academic.oup.com
Objective In 2020, the Canadian Vasculitis Research Network (CanVasc) published their
updated recommendations for the management of ANCA-associated vasculitides (AAV). The …
updated recommendations for the management of ANCA-associated vasculitides (AAV). The …
CanVasc recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides–Executive summary
…, TE Towheed, J Trudeau… - … Journal of Kidney …, 2015 - journals.sagepub.com
The Canadian Vasculitis research network (CanVasc) is composed of physicians from
different medical specialties, including rheumatology and nephrology and researchers with …
different medical specialties, including rheumatology and nephrology and researchers with …
[HTML][HTML] Development of Canadian recommendations for the management of ANCA-associated vasculitides: results of the national needs assessment questionnaire
…, R Taylor-Gjevre, T Towheed, J Trudeau… - The Open …, 2015 - ncbi.nlm.nih.gov
Objectives: To study variations in Canadian clinical practice patterns for the management of
ANCA-associated vasculitis (AAV) and identify points to consider for the development of …
ANCA-associated vasculitis (AAV) and identify points to consider for the development of …
[HTML][HTML] Measuring the impact of an educational intervention in rheumatoid arthritis: An open-label, randomized trial
…, S Côté, G Boily, R Lui, A Ikic, J Trudeau… - Archives of …, 2022 - ncbi.nlm.nih.gov
Objectives This study aims to determine whether patients with active rheumatoid arthritis (RA),
either starting on or changing biological or targeted synthetic disease-modifying …
either starting on or changing biological or targeted synthetic disease-modifying …
Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.
SE Wenzel, JB Trudeau, DA Kaminsky… - American journal of …, 1995 - atsjournals.org
To investigate the contribution of leukotrienes (LTs) to inflammation and bronchoconstriction
in nocturnal asthma, we performed a randomized trial in 12 asthmatic patients and 6 normal …
in nocturnal asthma, we performed a randomized trial in 12 asthmatic patients and 6 normal …
Neratinib+ capecitabine versus lapatinib+ capecitabine in patients with HER2+ metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: Findings …
…, WJ Gradishar, N Masuda, M Palacova, ME Trudeau… - 2019 - ascopubs.org
1002 Background: NALA (ClinicalTrials.gov NCT01808573) is a multinational, randomized,
open-label, phase III trial of neratinib (an irreversible pan-HER tyrosine kinase inhibitor [TKI]) …
open-label, phase III trial of neratinib (an irreversible pan-HER tyrosine kinase inhibitor [TKI]) …